BioCentury | Oct 16, 2019
Product Development

Relmada data offer hope of safer option for depression

...weeks. But the label for Spravato, which is the (S) enantiomer of the psychotropic drug ketamine...
...for a compound that can untangle the antidepressant and psychotomimetic effects of ketamine (see “Dissociating Ketamine”...
BioCentury | May 23, 2019
Company News

ICER questions price of DMD therapies, reviews MS and depression drugs

...superior to background antidepressants alone, but unanimously voted there was no difference between Spravato and ketamine...
BioCentury | Mar 28, 2019
Financial News

Antidepressant developer ATAI raises $43M series B round

...testing of the therapy this year as a rapid-acting antidepressant. Arketamine is an isomer of ketamine...
...This month, FDA approved Spravato esketamine from Johnson & Johnson (NYSE:JNJ), an (S) enantiomer of ketamine...
BioCentury | Mar 6, 2019
Company News

FDA approves Janssen's fast-acting depression therapy esketamine

...Management advisory committees voted last month in favor of recommending approval the (S) enantiomer of ketamine...
BioCentury | Feb 15, 2019
Clinical News

FDA panel backs Janssen's fast-acting depression treatment

...Safety and Risk Management advisory committees abstained from the vote on the (S) enantiomer of ketamine...
BioCentury | Feb 13, 2019
Company News

FDA panel backs Janssen's fast-acting depression treatment

...Safety and Risk Management advisory committees abstained from the vote on the (S) enantiomer of ketamine...
BioCentury | Feb 1, 2019
Company News

Seelos closes reverse-merger with Apricus

..."CNS Company Seelos Reverse Merging with Apricus" ). Seelos' pipeline includes SLS-002, an intranasal racemic ketamine...
BioCentury | Jan 11, 2019
Clinical News

NeuroRx's NRX-101 improves depression and suicidality in Phase II

...double-blind, U.S. trial received NRX-101 or lurasidone after stabilization with a single IV infusion of ketamine...
BioCentury | Aug 31, 2018
Company News

CNS company Seelos reverse merging with Apricus

...Seelos' pipeline includes two compounds that have completed Phase II testing: SLS-002, an intranasal racemic ketamine...
BioCentury | Feb 14, 2018
Preclinical News

Three targets in the same brain region could alleviate depression

...A Zhejiang University team published a pair of papers in Nature suggesting ketamine works by modulating...
...targets in the brain structure that could be used to create a more selective therapy. Ketamine...
...NYSE:JNJ) has a version of the drug, esketamine, in Phase III for the indication. However, ketamine...
Items per page:
1 - 10 of 97